Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics

Since conventional chemotherapy for acute myeloid leukemia (AML) has its limitations, a theranostic platform with targeted and efficient drug transport is in demand. In this study, we developed the first CD123 (AML tumor marker) aptamers and designed a novel CD123-aptamer-mediated targeted drug trai...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Haibin, Wang, Meng, Dai, Bo, Zhang, Yanmin, Yang, Ying, Li, Qiao, Duan, Mingyue, Zhang, Xi, Wang, Xiaomei, Li, Anmao, Zhang, Liyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241133/
https://www.ncbi.nlm.nih.gov/pubmed/28845698
http://dx.doi.org/10.1080/10717544.2017.1367976

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241133/
https://www.ncbi.nlm.nih.gov/pubmed/28845698
http://dx.doi.org/10.1080/10717544.2017.1367976

Ejemplares similares